Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13379919 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL13379918 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL3045916 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL5543844 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL3044611 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL3036936 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL3053577 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL10871667 | 0.82 | EPHX2 (0.45) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7245886 | 0.81 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4POLB | |
| SCHEMBL7357671 | 0.81 | SLC15A1 (0.44) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | SLC6A2 1513/4885SLC6A3 2750/4885SLC6A4 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.